Clinical Trial Update: Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) [Phase 2]

View source ↗

Summary

Phase 2 trial RELEVENT evaluates ramucirumab with carboplatin and paclitaxel for untreated thymic carcinoma or B3 thymoma with carcinoma. The current status of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Claudia Proto | Conditions: Thymic Carcinoma, Thymoma | Phase 2 | Status: UNKNOWN